Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.21.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 7,418 $ 5,413
Receivables 265 884
Inventory 129 328
Prepaid expenses and other current assets 846 522
Discontinued operations - current assets 187 181
Total current assets 8,845 7,328
Property and equipment, net 468 618
Operating lease right-of-use asset 324 141
Total assets 9,637 8,087
Current liabilities:    
Accounts payable 386 1,253
Accrued clinical trials expenses 14 214
Other accrued liabilities 303 319
Operating lease liability, current 109 150
Current portion of long-term debt 0 327
Discontinued operations - current liabilities 1,113 1,960
Total current liabilities 1,925 4,223
Operating lease liability, noncurrent 216 0
Long-term debt 0 332
Total liabilities 2,141 4,555
Commitments and contingencies (Note 6)
Stockholders' equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 9,864,158 and 7,139,068 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 10 7
Additional paid-in capital 381,001 370,804
Accumulated deficit (373,515) (367,279)
Total stockholders' equity 7,496 3,532
Total liabilities and stockholders' equity $ 9,637 $ 8,087